Link Asia International MedTech : (1) UPDATE ON FORMING THE JOINT VENTURE; (2) RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF GENERAL MANAGER OF JOINT VENTURE; AND (3) NON-COMPLIANCE WITH RULES 3.10 AND 3.21 OF THE LISTING RULES

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

Link-Asia International MedTech Group Limited

環 亞 國 際 醫 療 科 技 集 團 有 限 公 司

(incorporated in the Cayman Islands with limited liability)

(Stock code: 1143)

1. 1. UPDATE ON FORMING THE JOINT VENTURE;
2. RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR AND APPOINTMENT OF GENERAL MANAGER OF JOINT VENTURE;

AND

1. NON-COMPLIANCEWITH RULES 3.10 AND 3.21 OF THE LISTING RULES

Reference are made to the announcement (the ''Announcement'') issued by Link-Asia International MedTech Group Limited (the ''Company'') dated 18 March 2021. Unless otherwise defined, capitalised terms used herein shall have the same meanings as those defined in the Announcement.

UPDATE ON FORMING THE JOINT VENTURE

The board of the Company is pleased to announce that on 19 April 2021 (after trading hours), Huashi Management Consulting (Shenzhen) limited* (華氏管理諮詢（深圳）有限公司 the ''HuaShi''), which is a directly wholly-owned subsidiary of the Company, entered into formal joint venture agreement (the ''Agreement'') with Hanguang Technology. According to the Agreement, (i) Huashi and Hanguang Technology will hold 51% and 49% of equity interest of JV Company, respectively; and (ii) the JV Company will principally engage in the business of endometrial stem cell storage and fertility health management.

Upon completion the formation of the JV Company, Mr. Wang Xuejun will be appointed as the chairman, while Dr. Sun Xiaohu (''Dr. Sun''), an independent non-executive director of the Company, will be appointed as the general manager of the JV Company. At the same time, other team members with rich experience in biotechnology development and application will be introduced to join the JV Company.

The Board believes that under the leadership of the management team of the JV Company, the industrial chain layout of the group in the fields of assisted reproductive technology and cell technology will be gradually implemented, and it is expected that the JV Company will bring positive income and profit contribution to the Company.

- 1 -

As all the applicable percentage ratios (as defined under the Listing Rules) in respect of the transactions contemplated under the Agreement are less than 5%, the transactions contemplated under the Agreement do not constitute a notifiable transaction of the Company under Chapter 14 of the Listing Rules.

RESIGNATION OF AN INDEPENDENT NON-EXECUTIVE DIRECTOR

Dr. Sun has tendered his resignation as an independent non-executive Director and cease to be the member of the audit committee of the Company (the ''Audit Committee'') with effect from 19 April 2021 because he will involve in the medical business of the joint venture to be set up by the Company and take the role of its general manager.

Dr. Sun has confirmed that he has no disagreement with the Board and there are no others matters in respect of his resignation that need to be brought to the attention of the shareholders of the Company and The Stock Exchange of Hong Kong Limited. The Board would like to express its sincere gratitude to Dr. Sun for his valuable contribution to the Company during his tenure of service.

NON-COMPLIANCE WITH RULES 3.10 AND 3.21 OF THE LISTING RULES

Upon the resignation of Dr. Sun, the number of independent non-executive Directors and members of the Audit Committee fell below the requirements under Rules 3.10 and 3.21 of Listing Rules.

The Company will use its best endeavours to identify suitable candidate to fill the vacancies as soon as practicable, with the relevant appointment to be made within three months from 19 April 2021 pursuant to Rules 3.11 and 3.23 of the Listing Rules. Further announcement will be made by the Company as and when appropriate.

On behalf of the Board

Link-Asia International MedTech Group Limited

Lin Dailian

Chairman and executive Director

Hong Kong, 19 April 2021

As at the date of this announcement, the Board comprises Mr. Lin Dailian (Chairman), Mr. Wang Guozhen, Mr. Duan Chuanhong and Mr. Xia Xiaobing as executive Directors; Mr. Li Huiwu and Mr. Yang Weidong as independent non-executive Directors.

• For identification purposes only

- 2 -